Glowing Cornell dots -- a potential cancer diagnostic tool set for human trials

Jun 13, 2011

The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.

A paper describing this new medical technology, "Multimodal silica are effective cancer-targeted probes in a model of human ," will be published June 13, 2011 in the (July 2011). This is a collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC), Cornell University, and Hybrid Silica Technologies, a Cornell business start-up.

For the first time, scientists report a uniquely advanced and comprehensive characterization of Cornell Dots – an ultra small, cancer-targeted, multimodal silica nanoparticle – which has recently been approved as an "investigational new drug" (IND) by the FDA for a first-in-human clinical trial, says Michelle S. Bradbury, M.D., of the Memorial Sloan-Kettering Cancer Center and an assistant professor of radiology at Weill Cornell Medical College.

Cornell Dots are silica spheres less than 8 nanometers in diameter that enclose several dye molecules. The silica shell, essentially glass, is chemically inert and small enough to pass through the body and out in the urine. For clinical applications, the dots are coated with polyethylene glycol (PEG) so the body will not recognize them as foreign substances.

A guiding light within the body: To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces or even specific locations within tumors can be attached to the PEG shell. When exposed to near-infrared light, the dots fluoresce much brighter than dye to serve as a beacon to identify the target cells. The technology, the researchers say, enables visualization during surgical treatment, showing invasive or metastatic spread to lymph nodes and distant organs, and can show the extent of treatment response.

Hooisweng Ow, a coauthor of the paper and once a graduate student working with Ulrich Wiesner, Cornell Professor of Materials Science and Engineering, developed first-generation Cornell dots in 2005. Together, Wiesner, Ow and Kenneth Wang, have co-founded the company Hybrid Technologies (HST) to commercialize the invention. The combined team of MSKCC, Cornell and HST researchers is now in the process of forming a new commercial entity in New York City that will help transition the research into commercial products that will benefit cancer patient care.

"This is the first FDA IND approved inorganic particle platform of its class and properties that can be used for multiple clinical indications, two of which are explored: cancer targeting for diagnostics and future therapeutic diagnostics, as well as cancer disease staging and tumor burden assessment via lymph node mapping," says Bradbury.

The Cornell Dots were optimized for efficient renal clearance, allowing the body to pass them through the kidneys.

In addition, the scientists were able to perform real-time imaging of lymphatic drainage patterns and particle clearance rates, as well as sensitively detect nodal metastases. Nodal mapping is now being pursued under a new award of a BioAccelerate NYC Prize from the Partnership for New York City and the New York City Economic Development Corporation, which is expected to lead to another clinical trial in humans.

The lead authors of the paper are Miriam Benezra and Oula Penate-Medina, who are researchers at MSKCC. Bradbury and Wiesner are the senior authors.

Explore further: Nanocontainers for nanocargo: Delivering genes and proteins for cellular imaging, genetic medicine and cancer therapy

Related Stories

New genre of sugar-coated 'quantum dots' for drug delivery

Mar 04, 2009

(PhysOrg.com) -- Scientists in Switzerland are reporting an advance that could help tap the much-heralded potential of “quantum dots”— nanocrystals that glow when exposed to ultraviolet light — in the treatment of ...

Cornell makes cancer vaccine for clinical use

Aug 20, 2009

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein—a cancer vaccine—that will be used in clinical trials for patients facing either ovarian cancer or melanoma. ...

Coated Ultrasmall Quantum Dots Suitable for In Vivo Imaging

Dec 03, 2007

Quantum dots have shown promise in a variety of imaging and therapeutic applications, particularly when they are coated to render them biocompatible. However, such coating can increase the size of quantum dots signficantly, ...

Recommended for you

Twisted graphene chills out

Sep 17, 2014

(Phys.org) —When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

fmfbrestel
not rated yet Jun 13, 2011
Best of luck to you in your trial, if this pans out as hoped it will revolutionize cancer detection and treatment.

Next step if these fluorescing Cornell Dots work: attaching particles that react strongly to radiation so lower radiation doses do more damage to just the tumors.